BChE ALBUMIN FUSIONS FOR THE TREATMENT OF COCAINE ABUSE
A method of attenuating a biological effect of cocaine exposure in a primate. Such method includes administering to the primate an amount of a BChE-albumin fusion protein comprising the amino acid substitutions A227S, S315G, A356W, and Y360G, wherein the amount of the fusion protein is effective to cause attenuation of the biological effect of cocaine exposure in the primate.
Latest TEVA PHARMACEUTICAL INDUSTRIES, LTD. Patents:
This application is a continuation of U.S. Ser. No. 12/962,410, filed Dec. 7, 2010, now U.S. Pat. No. 8,541,373, issued Sep. 24, 2013, which claims the benefit of U.S. Provisional Application Nos. 61/283,791, filed Dec. 8, 2009 and 61/412,205, filed Nov. 10, 2010, each of which is hereby incorporated by reference in its entirety.
Throughout this application various publications, published patent applications, and patents are referenced. The disclosures of these documents in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.
BACKGROUNDCocaine abuse and dependence have disastrous medical and social consequences which have made the development of an effective treatment a high priority (Pan, Y., Gao, D., Yang, W., Cho, H., Yahg, G., Tai, H., Zhan, C., “Computational redesign of human butyrylcholinesterase for anticocaine medication,” PNAS, 102(46):16656-61, 2005). However, as stated by Brimijoin et al.: “there is no reliable means to treat cocaine overdose or reduce the likelihood of relapse in users who have achieved abstinence. Human plasma butyrylcholinesterase (BChE) contributes to normal cocaine metabolism and has been considered for use in treating cocaine toxicity” (Brimijoin, S., Gao, Y., Anker, J., Gliddon, L., LaFleur, D., Shah, R., Zhao, Q., Singh, M., Carroll, M., “A Cocaine Hydrolase Engineered from Human Butyrylcholinesterase Selectively Blocks Cocaine Toxicity and Reinstatement of Drug Seeking in Rats,” Neuropsychopharmacology, 33:2715-25, 2008).
Wild-type BChE, while important for cocaine metabolism in the body, has low catalytic efficiency with cocaine. The low cocaine hydrolase activity of wild-type BChE would require the use of prohibitively large quantities of purified enzyme for treatment of cocaine abuse or overdose. Mutagenesis performed on human BChE with the goal of enhancing the cocaine hydrolase activity resulted in the development of the double mutant A328W/Y332A (residues 356 and 360 relative to full length BChE) that has a kcat that is 40-fold higher than wild-type BChE, with only a slightly increased KM (Sun H., Shen M., Pang Y., Lockridge O., Brimijoin S., “Cocaine Metabolism Accelerated by a Re-Engineered Human Butyrylcholinesterase” Journal of Pharmacology and Experimental Therapeutics, 302(2):710-716, 2002).
Further experimentation utilizing molecular dynamics to simulate the transition state for the first chemical reaction step of BChE catalyzed hydrolysis of cocaine resulted in the BChE mutant A227S/S315G/A356W/Y360G that has a catalytic efficiency which is 500-fold greater than wild-type BChE and is greater than other previously designed BChE mutants (Pan, Y., Gao, D., Yang, W., Cho, H., Yang, G., Tai, H., Zhan, C., “Computational redesign of human butyrylcholinesterase for anticocaine medication,” PNAS, 102(46):16656-61, 2005).
To obtain a form of the A227S/S315G/A356W/Y360G BChE mutant that may be suitable for therapeutic use, the BChE mutant designed by Pan et al. was fused at its C terminus to human serum albumin (HSA) because it has been observed that similar fusions exhibit favorable pharmacokinetic properties with high stability and extended plasma half lives. It was observed that the BChE-albumin fusion comprising the above mutations retains high catalytic efficiency with cocaine and exhibits a plasma half-life of 8 hours after i.v. injection to rats. (Brimijoin S., Gao, Y., Anker J., Gliddon L., LaFleur D., Shah R., Zhao, Q., “A Cocaine Hydrolase Engineered from Human Butyrylcholinesterase Selectively Blocks Cocaine Toxicity and Reinstatement of Drug Seeking in Rats” Neuropsychopharmacology, 33:2715-25, 2008).
To date, there has been no effective method for treating cocaine abuse or overdose in primates developed that utilizes a BChE-albumin fusion comprising the mutations A227S, S315G, A356W, and Y360G.
BRIEF SUMMARY OF THE INVENTIONThe subject invention provides a method of attenuating a biological effect of a cocaine exposure in a primate comprising administering to the primate an amount of a fusion protein comprising
-
- (a) a mutant butyrylcholinesterase (BChE) polypeptide comprising the sequence
-
- (b) a human serum albumin (HSA) polypeptide comprising the sequence
and
-
- (c) a signal peptide comprising the sequence MRPTWAWWLFLVLLLALWAPARG (SEQ ID NO:3),
wherein the amount of the fusion protein is effective to cause attenuation of the biological effect of the cocaine exposure in the primate.
- (c) a signal peptide comprising the sequence MRPTWAWWLFLVLLLALWAPARG (SEQ ID NO:3),
The subject invention provides a method of attenuating a biological effect of a cocaine exposure in a primate comprising administering to the primate an amount of a fusion protein comprising
-
- (a) a mutant butyrylcholinesterase (BChE) polypeptide comprising the sequence
-
- (b) a human serum albumin (HSA) polypeptide comprising the sequence
and
-
- (c) a signal peptide comprising the sequence MRPTWAWWLFLVLLLALWAPARG (SEQ ID NO:3),
wherein the amount of the fusion protein is effective to cause attenuation of the biological effect of the cocaine exposure in the primate.
- (c) a signal peptide comprising the sequence MRPTWAWWLFLVLLLALWAPARG (SEQ ID NO:3),
In an embodiment of the method, fusion protein comprises the sequence
In another embodiment of the method, the fusion protein is administered prior to the cocaine exposure.
In another embodiment, the fusion protein is administered up to one day prior to the cocaine exposure.
In another embodiment, the fusion protein is administered up to 216 hours prior to the cocaine exposure. The fusion protein may be administered 1, 2, 3, 4, 5, 6, 7, 8, or 9 days prior to the cocaine exposure.
In yet another embodiment of the method, the fusion protein is administered after the cocaine exposure. In a further embodiment, the fusion protein is administered up to six hours following the cocaine exposure. In another embodiment, the fusion protein is administered up to one hour after the cocaine exposure.
In yet another embodiment of the method, the cocaine exposure is a single cocaine exposure.
In yet another embodiment of the method, the cocaine exposure is a recurring cocaine exposure. In a further embodiment of the method, the recurring cocaine exposure is cocaine abuse or cocaine dependence.
In yet another embodiment of the method, the recurring cocaine exposure comprises at least six single cocaine exposures in a twelve month period.
In yet another embodiment of the method, the recurring cocaine exposure comprises at least twenty single cocaine exposures during the primate's lifetime.
In yet another embodiment of the method, the biological effect is caused by cocaine overdose in the primate and the attenuating is treating or preventing the biological effect.
In yet another embodiment of the method, the biological effect is an increase in blood pressure.
In a further embodiment of the method, the duration of the increase in blood pressure is reduced by 60-90%.
In a further embodiment of the method, the duration of the increase in blood pressure is reduced by about 78%.
In yet another embodiment of the method, the biological effect is an increase in heart rate or body temperature. In a further embodiment of the method, the degree of attenuation is 45%-70%.
In a further embodiment of the method, the degree of attenuation is 57%.
In yet another embodiment of the method, the biological effect is cocaine seeking behavior in the primate.
In yet another embodiment of the method, the cocaine seeking behavior occurs during a period of cocaine abstinence following the cocaine exposure.
In yet another embodiment of the method, the cocaine seeking behavior follows a relapse.
In yet another embodiment of the method, administration of the fusion protein two hours before the relapse attenuates cocaine seeking behavior by the primate immediately following the relapse.
In yet another embodiment of the method, administration of the fusion protein two hours before the cocaine exposure results in a 50% to 100% reduction in the cocaine seeking behavior by the primate.
In yet another embodiment of the method, attenutation of cocaine seeking behavior is observed up to four days following administration of the fusion protein.
In yet another embodiment of the method, the administration of the fusion protein results in a lowering of total cocaine exposure in the primate than without the administration.
In yet another embodiment of the method, attenuating cocaine seeking behavior results in a period of cocaine abstinence in the primate. In a further embodiment of the method, the period of abstinence is 2 weeks to 3 weeks.
In yet another embodiment of the method, attenuating cocaine seeking behavior results in a larger proportion of days in which the primate is not exposed to cocaine than without the administration.
In yet another embodiment of the method, attenuating cocaine seeking behavior results in a larger number of consecutive days in which the primate is not exposed to cocaine than without the administration.
In yet another embodiment of the method, attenuating cocaine seeking behavior results in a lessening of severity of cocaine dependence or abuse as evaluated by the cocaine selective severity assessment (CSSA) or Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV).
In yet another embodiment of the method, the effective amount of the fusion protein is an amount which reduces the primate's serum cocaine level to about 0 ng/ml within about 30 minutes of a 1 mg/kg intravenous cocaine dose.
In yet another embodiment of the method, the administration of the fusion protein reduces the primate's serum cocaine level to less than 12% of the serum cocaine level without the administration within about 5 minutes of a 1 mg/kg intravenous cocaine dose.
In yet another embodiment of the method, the administration of the fusion protein reduces the primate's serum cocaine level to 7% of the serum cocaine level without the administration within about 5 minutes of a 1 mg/kg intravenous cocaine dose.
In yet another embodiment of the method, the fusion protein is administered only once, daily, semi-weekly, weekly, bi-weekly, or monthly.
In another embodiment, the fusion protein is administered weekly or twice weekly.
In another embodiment, the fusion protein is administered as a single dose following the cocaine exposure.
In another embodiment, the fusion protein is administered as a single dose following a cocaine overdose.
In yet another embodiment of the method, the fusion protein is administered by intramuscular injection or subcutaneous injection.
In yet another embodiment of the method, the fusion protein is in a formulation buffer comprising 10 mM sodium phosphate, 200 mM mannitol, 60 mM trehalose, and 0.01% (w/v) polysorbate 80, pH 7.2.
In yet another embodiment of the method, the fusion protein is present in the formulation at a concentration of at least 30 mg/ml.
In yet another embodiment of the method, attenuation of the biological effect is observed up to 72 hours after administration of the fusion protein.
In yet another embodiment of the method, the primate is a human.
In a further embodiment of the method, the cocaine exposure is a single cocaine exposure of 10 mg to 60 mg or a recurring cocaine exposure wherein each single cocaine exposure of the recurring cocaine exposure is 10 mg to 60 mg.
In yet another embodiment of the method, the effective amount of the fusion protein is an amount which reduces the human's serum cocaine level to about 0 ng/ml within about 30 minutes of a 40 mg intravenous cocaine dose.
In yet another embodiment of the method, the effective amount of the fusion protein is 0.06 mg/kg to 5 mg/kg. In another embodiment of the method, the effective amount of the fusion protein is 0.06 mg/kg, 0.3 mg/kg, 1.6 mg/kg, or 4.8 mg/kg.
In yet another embodiment of the method, the effective amount of the fusion protein is 50 mg to 300 mg. In another embodiment of the method, the effective amount of the fusion protein is 50 mg, 100 mg, 150 mg, or 300 mg.
An embodiment of the BChE-albumin fusion protein comprising the amino acid substitutions A227S, S315G, A356W, and Y360G is shown in
It is understood that all combinations of the above described embodiments of the invention are within the scope of the invention.
As used herein, “primate” refers to any of an order of mammals that are characterized especially by advanced development of binocular vision, specialization of the appendages for grasping, and enlargement of the cerebral hemispheres and that include humans, apes, monkeys, and related forms.
As used herein, “degree of attenuation” refers to the decrease in a biological effect of cocaine exposure that is observed following administration of a BChE-albumin fusion protein as compared to the biological effect of cocaine exposure observed in the absence of the BChE-albumin fusion protein. The degree of attenuation is calculated by the following formula:
For example, if cocaine exposure raises a baseline temperature of 38° C. to 38.7° C. in the absence of a BChE-albumin fusion protein, and cocaine exposure raises a baseline temperature of 38° C. to 38.3° C. in the presence of a BChE-fusion protein, the degree of attenuation is 57.1% ((0.7° C.−0.3° C.)/0.7° C.).
As used herein, “a single cocaine exposure” refers to one exposure of cocaine isolated from any other exposure of cocaine. “A recurring cocaine exposure” refers to more than one single cocaine exposure. The recurring cocaine exposure may be a regular or an irregular pattern of single cocaine exposures beginning with the second or subsequent single cocaine exposure in the subject. An individual experiencing recurring cocaine exposure may meet the criteria for cocaine dependence or cocaine abuse of the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV).
As used herein, the term “total cocaine exposure” refers to the aggregate cocaine exposure during a given time interval. Total cocaine exposure may be measured during or after a period of a treatment designed to attenuate cocaine seeking behavior or other biological effect of cocaine exposure.
As used herein, the term “a period of cocaine abstinence” refers to a period of time following cocaine exposure where the primate does not experience a new cocaine exposure.
As used herein, the term “relapse” refers to a cocaine exposure following a period of cocaine abstinence.
It is understood that where a parameter range is provided, all tenths of integers within that range are provided by the invention. For example, “0.2 mg/kg to 15 mg/kg” includes 0.2 mg/kg, 0.3 mg/kg, 0.4 mg/kg, 0.5 mg/kg etc. up to and including 15.0 mg/kg.
An animal dose may be converted to a human equivalent dose (HED) by using the conversion table found in the publication “Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers,” U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER), July 2005. Doses for cynomolgus monkeys in mg/kg may be converted to an HED in mg/kg by dividing the cynomolgus monkey dose by 3.1. Doses for squirrel monkeys in mg/kg may be converted to an HED in mg/kg by dividing the squirrel monkey dose by 5.3.
LIST OF ABBREVIATIONS
- AUC(0-t) Area under the plasma concentration-time curve from time zero up to time of last detectable concentration (tz)
- AUC(0-∞) Area under the plasma concentration-time curve from time zero to infinity
- % AUCex Percentage of AUC that is due to extrapolation from tz to infinity
- BChE butyrycholinesterase
- BQL Below Quantitation Limit
- CL clearance
- Cmax maximum concentration
- CocH cocaine hydrolase
- ELISA enzyme linked immunosorbent assay
- GFR glomerular filtration rate
- hr hour(s)
- HRP horseradish peroxidase
- IM intramuscular
- IV intravenous
- LLOQ lower limit of quantitation
- min minute(s)
- NCA noncompartmental analysis
- NIDA National Institute on Drug Abuse
- PBS phosphate buffered saline
- PD pharmacodynamics
- PK pharmacokinetics
- RT room temperature
- Rsq Coefficient of determination
- % RSD Percent Relative Standard Deviation
- SD Standard Deviation
- SC subcutaneous
- SOP standard operating protocol
- t1/2 half-life of the terminal phase
- tmax time of maximum concentration
- Vz volume of distribution from the terminal phase
The BChE-albumin fusion protein shown in
The objective of this trial was to determine the pharmacokinetic (PK) profile of AlbuBChE in male cynomolgus monkeys following a single intramuscular administration at 0.2, 1 or 5 mg/kg AlbuBChE dose levels and to determine AlbuBChE activity as a function of time by intravenous administration of 1 mg/kg dose of cocaine at 2, 48, 96, 120, and 240 hours after AlbuBChE dose administration.
RationaleAlbuBChE is a fusion protein of human serum albumin (HSA) and a genetically modified form of human butyrylcholinesterase (BChE) that exhibits high catalytic efficiency for the hydrolysis of cocaine to benzoic acid. AlbuBChE is under development as a potential intervention in preventing relapse to drug-seeking behavior. Fusion of a protein to albumin has been shown to improve the pharmacokinetic properties of the protein by reducing the clearance and extending the half-life. A longer half-life is expected to translate into a longer dosing interval and better compliance with a drug regimen.
Rationale for Species SelectionCynomolgus monkeys (macaca mulatta) were selected for this study based on anatomical, physiological, and biochemical similarities to humans, which may facilitate extrapolation of observed pharmacokinetic and pharmacodynamic properties to humans. Monkeys are known to express butyrylcholinesterase, which is a component of this drug. Monkeys are also physiologically responsive to cocaine.
Rationale for Dose Level and RouteIn a previous study, AlbuBChE pharmacokinetic profile was evaluated in cynomolgus monkeys. In that study, the test article was administered SC (7.8, 2.4 and 0.78 mg/kg), IM (2.4 mg/kg) and IV (2.4 mg/kg). The pharmacokinetic properties of AlbuBChE were linear throughout the SC doses measured. The choice of IM for this study was based on the greater bioavailability in IM as compared to SC (79% and 35-39% respectively) observed in the previous study. In addition, AlbuBChE IM dose levels of 0.2, 1 and 5 mg/kg were selected to define AlbuBChE pharmacodynamic range in cynomolgus monkeys.
The dose of cocaine at 1 mg/kg IV was selected as a dose sufficiently high to yield a physiologically relevant response and achieve measureable concentration of cocaine in blood, while not excessively stimulating the animals.
The number of animals in each group is the minimum number of animals per group necessary for assessment of inter animal variability. As this is a pilot study, only one sex (males) was evaluated.
Test SolutionsThe test article, AlbuBChE, was stored in a stock solution as a frozen liquid formulation containing 29.9 mg/mL at −70±15° C. Prior to dosing, the test article formulation was thawed at room temperature. When the test article formulation was completely thawed, the container was mixed by gentle inversion and diluted with the appropriate volume of test article diluent to achieve a concentration of 20 mg/mL. This formulation was serially diluted with the test article diluent to achieve concentrations of 4 and 0.8 mg/mL.
Cocaine hydrochloride, the pharmacodynamic test article, was purchased from Sigma. Dose levels were expressed as the hydrochloride salt.
Experimental DesignThe study included a total of 11 naüve, adult male cynomolgus monkeys dividied into four dose groups:
a control group of two cynomologus monkeys that only received a single IV dose of cocaine;
three dose groups that were treated with a single IM dose of AlbuBChE at 0.2, 1 or 5 mg/kg. Three naïve, adult male cynomolgus monkeys were used in each dose group. Following AlbuBChE treatment, a 1 mg/kg IV dose of cocaine was administered at 2, 48, 96, 120, and 240 hours after AlbuBChE dose administration.
A summary of the dose designation and dose levels can be found in Table 1. Individual doses were calculated based on body weights recorded on the day of dose administration. Animals were not fasted prior to dose administration.
A single intramuscular (IM) administration of AlbuBChE was administered on study day 1 and blood was collected at the time points outlined in Table 2. Approximately 0.5 mL of whole blood was collected from the femoral vein into serum separate tubes (SST).
Approximately 0.5 mL of whole blood was collected from the femoral vein at 5, 10, 15, 20, 30, 40 and 60 minutes following each dose of cocaine (Study Day 1 of the control group and Study Day 1 (2 hr), 3 (48 hr), 5 (96 hr), 6 (120 hr), and 11 (240 hr) post-AlbuBChE dose administration). Blood was placed into K2EDTA blood collection tubes with esterase inhibitor diisopropylfluorophosphate (DFP). Tubes were inverted several times and placed on wet ice upon collection. Samples were centrifuged at 2-8° C. within 45 minutes of collection. The resultant plasma was recovered and a single 200 μL aliquot of plasma was placed into polypropylene tubes. Plasma samples were frozen over dry ice and stored at −75±15° C.
Assay MethodsThe following outline describes the ELISA-based assay employed in the measurement of AlbuBChE concentrations in monkey serum samples obtained pre-administration and at different times after administration.
Immulon 4 HBX plates are coated with 100 μL of anti-BChE mAb 002-01 (Abcam ab17246) at 1 ug/mL in PBS, overnight at 4° C. Blocking is done with 2% Casein in 1×PBS, 200 μL/well, 2 hours at room temperature. After washing, 100 μL of diluted serum samples are added to the plates along with standards. Standards are generated through 3.64 fold, serial dilution of AlbuBChE from 2000 to 3.1 ng/mL. Serum samples and standards are maintained at 10% serum by dilution with buffer containing pooled cynomolgus monkey serum. A wash step precedes detection with 100 μL of anti-HSA mAb-6502-HRP at 0.04 μg/mL for 1 hour. Wells are washed again, prior to developing with 100 μl of TMB substrate. After 15 minutes, the reaction is terminated with 100 μL/well of 1N H2SO4 and read on SpectraMax plate reader at 450/570 nm. Values for unknown serum samples are calculated by interpolation of standard curve generated by 4-parameter fit of AlbuBChE standards. The limit of quantitation in cynomolgus serum was 21.1 ng/mL.
LC-MS Quantitation of Cocaine in SerumThe following outline describes the LC-MS-based assay employed for the measurement of cocaine in plasma samples. Prior to MS analysis, plasma samples, calibration standards and controls were extracted using supported liquid extraction (SLE-ISOLUTE, Biotage). Twenty-five microliters of samples (25 μL) received 150 μl of 5% Ammonium hydroxide and 25 μl internal standard solution (Cocaine-d3). After mixing and transfer to SLE plate, samples were eluted with methylene chloride and evaporated to dryness. After resuspension in 50 μl of reconstitution solution—5% ACN in 10 mM ammonium acetate in water, 10 μl was injected onto Thermo Hypercarb column at 0.5 ml/min. Mobile phase was biphasic. Mass spectrophotometric detection was performed using Api 4000, APCI positive interface and Multiple Reaction Monitoring (MRM). Plasma concentrations of cocaine, benzoylecgonine and ecgonine methyl ester were determined using this assay.
PK Analysis of AlbuBChEAlbuBChE pharmacokinetic parameter values were determined using serum concentration-time profiles for individual animals. The computer software WinNonlin Professional (Version 4.0.1 Pharsight Corporation, USA) was used. Specifically the model for non-compartmental analysis with extravascular input was applied. If there were fewer than 3 data points in the terminal phase of the serum concentration curve, a terminal phase half-life and PK parameters derived from the half-life were not calculated for that profile. Parameters analyzed include tmax, Cmax, t1/2, AUC(0-t) and AUC(0-∞) were calculated.
PK Analysis of CocaineWhen the data permits, pharmacokinetic parameter values for cocaine and its metabolites were determined using plasma concentration-time profiles for individual animals at all the study days of cocaine administration. The computer software WinNonlin Professional (Version 4.0.1 Pharsight Corporation, USA) was used. Specifically the model for non-compartmental analysis with IV bolus input for cocaine and extravascular input for the metabolites. If there were fewer than 3 data points in the terminal phase of the plasma concentration curve, a terminal phase half-life and PK parameters derived from the half-life were not calculated for that profile.
PK/PD AnalysisAlbuBChE PK/PD relationship was defined using the computer software WinNonlin Professional (Version 4.0.1 Pharsight Corporation, USA). Specifically the direct sigmoidal inhibitory Effect Emax model was use in which maximum effect (Emax) as measured by cocaine AUC was assumed at AlbuBChE concentration of zero. The model equation can be described as follows:
Inhibitory Effect Sigmoid Emax, C=0 at Emax, C=infinity at Eo
E=Emax−(Emax−E0)*(C**Gamma/(C**Gamma+EC50**Gamma))
The sigmoidal model was selected due to the higher activity observed at the 48 hr timepoint compared to the 2 hr timepoint.
The PD parameter used in the analysis was cocaine AUC. PK parameters used in the model were AlbuBChE plasma concentrations at 2, 48, 96, 120, and 240 hr post-AlbuBChE dose. Due to the fact that AlbuBChE concentration was not measured at 2 hr post-AlbuBChE dose, the concentration at 3 hr postdose was used in the analysis with the assumptions that AlbuBChE concentration at 3 hr post AlbuBChE dose may reflect AlbuBChE conc. at 2 hr post AlbuBChE dose.
Statistical MethodsSummary statistics of the concentration profiles and PK parameter values by experimental group were calculated using the descriptive statistics function in WinNonlin. Statistical parameters reported are N, mean, SD and percent coefficient of variation (% CV).
Results AlbuBChE Concentration ProfileAlbuBChE concentration-time data and summary statistics are listed in Tables 3 and 4. Individual animal AlbuBChE serum concentration-time profiles following a single AlbuBChE IM injection of 0.2, 1 or 5 mg/kg are shown in
Following IM injection, all animals had measurable AlbuBChE concentrations. Inter-animals variability per dose group appears to be reasonable as indicated by % CV that ranged from 8.2 to 78.4 for all time points. AlbuBChE serum concentration increased with increasing dose.
LC/MS analysis was performed on all samples to analyze for cocaine, benzoylecgonine and ecgonine methyl ester levels in monkey plasma. Mean plasma concentration-time profiles in control animals and following 0.2, 1, or 5 mg/kg can be found in Tables 5, 6, and 7 and
In general, cocaine plasma concentrations appear to decrease as a function of AlbuBChE dose and increase as a function of time post-AlbuBChE administration. Cocaine concentrations at 240 hr post-AlbuBChE administration appears to be in the same range as Day 1 cocaine control group (
As one might expect based on cocaine metabolic pathway (
Theoretically, plasma concentration of ecgonine methyl ester should increase following AlbuBChE administration (
AlbuBChE pharmacokinetic parameter values following a single IM dose of 0.2, 1 or 5 mg/kg AlbuBChE dose in individual animals and descriptive statistics per group can be found in Table 8. Mean PK parameter values for AlbuBChE following IM dosing at 0.2, 1 or 5 mg/kg are summarized in Table 9.
In general absorption from IM site of administration was rapid with measureable concentrations observed at the first sample collected (1 hr postdose). Maximum concentration was observed at 3 hr for the 0.2 and 1 mg/kg dose level. Tmax values was slightly longer (6 hr) for the 5 mg/kg dose.
AlbuBChE exposure increased with increasing dose. Dose normalized Cmax and AUC values appear to increase as a function of dose suggesting a more than proportional increase in exposure as a function of dose. This was also accompanied with a increase in terminal elimination t½ as a function of dose particularly between 1 and 5 mg/kg dose levels where t½ value almost doubled.
Summary table of mean cocaine pharmacokinetic values per dose group are presented in Table 10.
Cocaine pharmacokinetic profile was well characterized for all dose groups and time points with one exception: plasma concentration-time profile for the cocaine dose administered at 2 hr post-AlbuBChE dose was variable for all dose groups. As such, the terminal elimination t could not be accurately characterized in most of the animals on this cocaine dosing occasion.
Cocaine AUC(0-t) appears to decrease as a function of AlbuBChE dose and increase as a function of time post-AlbuBChE administration. Similarly, cocaine systemic plasma clearance appears to increase as a function of AlbuBChE dose and return to control values as a function of time post-AlbuBChE dose. At 240 hr post-AlbuBChE administration cocaine AUC and clearance appear to be in the same range as Day 1 cocaine control group.
For all three AlbuBChE dose levels, maximum AlbuBChE effect on cocaine clearance or AUC was observed at 48 hr postdose. The duration of effect was related to AlbuBChE dose levels. Following the 5 mg/kg dose, AlbuBChE effect on cocaine AUC and clearance was evident up to 120 hr postdose. At the 1 mg/kg dose, AlbuBChE effect on cocaine AUC or clearance may still be evident at 96 to 120 hr post-AlbuBChE dose relative to control or the 240 hr values. As AlbuBChE dose decreased to 0.2 mg/kg, so did the duration of effect with 48 hr being the last time point with elevated cocaine clearance. Based on this data, a once or twice weekly dosing regimen of AlbuBChE is likely.
As can be observed in
As can be observed in
Based on the mechanism of action of AlbuBChE it was anticipated that a direct effect inhibitory Emax model would be able to characterize the PK/PD relationship of AlbuBChE and cocaine.
PK and PD data used in the analysis are shown in Table 12. The fit resulting from the direct Sigmoidal inhibitory Effect Emax model are shown in
The data clearly shows the inverse relationship between AlbuBChE serum concentration and cocaine exposure. AlbuBChE serum concentration that may result in 50% decrease in cocaine concentration (EC50) was estimated by the model to be ˜600 ng/mL. Emax, E0, and Gamma values were 12909 (min*ng/mL), 1096 (min*ng/mL), and 0.708, respectively.
The animals were observed throughout the study. There were no deaths during the study, and there were no clinical or cageside observations associated with administration of AlbuBChE at either dose. Administration of cocaine at a dose of 1 mg/kg without pre-treatment with the test article resulted in hyperactivity and increased respiratory rate with abdominal breathing. Cocaine-related observations were not observed for five days following pre-treatment with the test article at AlbuBChE doses ranging from 0.2 to 5 mg/kg but returned on study days 6 and 11.
ConclusionsAlbuBChE was well tolerated in cyomolgus monkeys following a single IM dose of 0.2, 1 or 5 mg/kg.
AlbuBChE absorption from IM site of administration was rapid. Tmax was observed at 3 hr for the 0.2 and 1 mg/kg and 6 hr for the 5 mg/kg dose. AlbuBChE exposure appears to increase in a more than proportional manner as a function of dose. Terminal elimination t½ increased from 31 to 62 hr between 1 and 5 mg/kg dose levels.
Cocaine was administered to control animals on Day 1 and at 2, 48, 96, 120 and 240 hr post-AlbuBChE dose. After each cocaine administration, multiple samples were drawn with the objective of determining the pharmacokinetic profile in response to decreasing serum levels of AlbuBChE. Cocaine AUC(0-t) decreased as a function of AlbuBChE dose and increase as a function of time post-AlbuBChE administration.
The duration of effect was related to AlbuBChE dose levels. AlbuBChE effect on cocaine AUC and clearance was evident up to 120 hr for 5 mg/kg dose, 96-120 hr for 1 mg/kg dose and 48 hr for the 0.2 mg/kg dose. Based on this data, a once or twice weekly dosing regimen of AlbuBChE is likely.
PK/PD relationship in cynomolgus monkeys appears to indicate an inverse relationship between AlbuBChE serum concentration and cocaine exposure. AlbuBChE serum concentration that may result in 50% decrease in cocaine concentration (EC50) was estimated by the direct Sigmoidal Inhibitory Effect Emax model model to be ˜600 ng/mL.
Example 2 AlbuBChE Pharmacokinetic Pharmacodynamic (PK/PD) Study in Squirrel Monkeys ObjectiveTo evaluate AlbuBChE pharmacokinetics and pharmacodynamics following a single 5 mg/kg intramuscular injection of AlbuBChE to Squirrel monkeys. AlbuBChE pharmacodynamic effect was measured following cocaine IV administration at a dose of 1 mg/kg in control animals or at 2, 72 and 96 hr post-AlbuBChE dose.
Study DesignDose Level: AlbuBChE dose level of 5 mg/kg was selected based upon prior studies in Cynomolgous monkeys in which this dose level was found to be effective in decreasing cocaine exposure. Cocaine IV dose of 1 mg/kg was based on literature reports that such dose is sufficient to cause an effect in monkeys without causing excessive hyperactivity. The IM route of administration for AlbuBChE dosing was selected because this is an intended route of administration to humans.
Blood samples (0.4 mL) were collected from the femoral vein and placed into serum separator tubes (SST) at pre-dose, 24, 72, 96 & 336 hrs post-dose (samples collected at 336 hr (14 days) post-dose were intended to evaluate immunogenicity. The samples were also analyzed for AlbuBChE concentration). Tubes were maintained at room temperature for at least 1 hour, but not to exceed 4 hours prior to centrifugation. Samples were centrifuged and at least 200 μL of serum was harvested and maintained on dry ice prior to storage at approximately −70° C.
Cocaine Pharmacokinetic SamplesApproximately 0.4 mL of whole blood was collected from the femoral vein after every cocaine dose at 5 and 30 minutes postdose. Blood was placed into K2EDTA blood collection tubes with esterase inhibitor (diisopropylfluorophosphate (DFP). Tubes were inverted several times and placed on wet ice upon collection. Samples were centrifuged at 2-8° C. within 45 minutes of collection. The resultant plasma will be recovered and a single 200 μL aliquot of plasma was placed into polypropylene tubes. Plasma samples was frozen over dry ice and stored at approximately −70° C.
AlbuBChE Sample AnalysisThe following paragraph briefly describes the ELISA based assay employed in the measurement of AlbuBChE concentrations in serum samples.
Immulon 4 HBX plates are coated with 100 ul of anti-human BChE mAb 002-01 (Abcam ab17246) at 1 μg/mL in PBS, overnight at 4 C. Blocking is done with 2% casein in phosphate buffered saline (PBS), 200 μL/well, 2 hours at room temperature. After washing, 100 μL of diluted serum samples are added to the plates along with standards. Standards are generated through 2.6 fold, serial dilution of AlbuBChE from 420 to 5.2 ng/mL. Serum samples and standards are maintained at 10% serum by dilution with buffer containing pooled cynomolgus monkey serum. A wash step precedes detection with 100 μl of anti-HSA mAb-6502-HRP at 0.04 μg/mL for 1 hour. Wells are washed again, prior to developing with 100 μL of tetramethylbenzidine substrate. After 15 minutes the reaction is terminated with 100 μL/well of 1N H2SO4 and read on SpectraMax plate reader at 450/570 nm. Values for unknown serum samples are calculated by interpolation of standard curve generated by 5-parameter fit of AlbuBChE standards. Serum samples collected at predose and on Day 14 postdose were also analyzed for immunogenicity.
AlbuBChE Pharmacokinetic and PK/PD AnalysisAlbuBChE pharmacokinetic parameter values were determined using serum concentration-time profiles for individual animals. The computer software WinNonlin Professional (Version 4.0.1 Pharsight Corporation, USA) was used. Specifically the model for non-compartmental analysis with extravascular input was applied.
In spite of the limited amount of data, an attempt was made to characterize PK/PD relationship. The computer software WinNonlin Professional (Version 4.0.1 Pharsight Corporation, USA) was used. Specifically the direct Inhibitory Effect Emax model was use in which Emax was assumed at AlbuBChE concentration of zero. The model equation can be described as follows:
E=Emax*(1−(C/(C+EC50)))
The PD parameter used in the analysis was cocaine plasma concentration at 5 min post-cocaine dose. PK parameters used in the model were AlbuBChE plasma concentrations at 2, 72 and 96 hr post-AlbuBChE dose. Due to the fact that AlbuBChE concentration was not measured at 2 hr post-AlbuBChE dose, the 1st time sample collected was used in the analysis (24 hr post-AlbuBChE dose) with the assumptions that AlbuBChE concentration at 24 hr post AlbuBChE dose may reflect AlbuBChE concentration at 2 hr post AlbuBChE dose. Due to the limited data and the assumptions used in the analysis, parameter values from this PK/PD analysis need to be viewed as approximate estimates.
Results AlbuBChETable 15 and
AlbuBChE terminal elimination slope was well characterized as indicated by Rsq values being higher than 0.9. Area under the curve was also well characterized as indicated by % AUC extrapolated being less than 20%. The initial absorption phase of AlbuBChE concentration-time profile was not characterized since the first sample was collected at 24 hr postdose. As such, Tmax and Cmax reported are apparent since actual Tmax can be expected to occur between 3 and 6 hr. AlbuBChE exposure was consistent for the three animals, with differences in levels only clearly evident after 2 weeks. For example, AUC values for the three animals were in a tight range with % CV of ˜7%. AlbuBChE terminal elimination t½ was estimated to range from 45.5 to 65.5 hr (average half-life of 56.6 hours).
Cocaine was administered IV at a dose of 1 mg/kg in control animals (n=2) or at 2, 72 and 96 hr post-AlbuBChE dose (n=3). The bioanalytical method measured the plasma concentration of cocaine and two of its metabolites: ecgonine methyl ester and benzoylecgonine. Cocaine metabolic pathway is shown in
Individual and mean cocaine plasma concentration (ng/mL) vs. time (hr) data in control and AlbuBChE treated Squirrel monkeys are shown in Table 17. A summary of the mean cocaine concentrations vs. time are shown in
Individual and mean ecgonine methyl ester plasma concentration (ng/mL) vs. time (hr) data in control and AlbuBChE treated Squirrel monkeys are shown in Table 18. A summary of the mean ecgonine methyl ester concentrations are shown in
Individual and mean benzoylecgonine plasma concentration (ng/mL) vs. time (hr) data in control and AlbuBChE treated Squirrel monkeys are shown in Table 19. A summary of the mean benzoylecgonine concentrations are shown in
In spite of the limited number of time points and animals, an attempt was made to characterize AlbuBChE PK/PD relationship in male Squirrel monkeys. PK and PD data used in the analysis are shown in Table 20. The individual data and the fit resulting from the direct Inhibitory Effect Emax model are shown in
AlbuBChE pharmacokinetic profile was characterized in three male Squirrel monkeys following a single IM 5 mg/kg AlbuBChE dose. Extent of variability in exposure was minimal (˜7%). AlbuBChE terminal elimination t1 was estimated to range from 45.5 to 65.5 hr.
Cocaine was administered IV at a dose of 1 mg/kg in control animals (n=2) or at 2, 72 and 96 hr post-AlbuBChE dose (n=3). AlbuBChE caused a decrease in cocaine exposure. The effect was most pronounced at 2 hr post-AlbuBChE dose (<7% of control). Cocaine exposure was ˜60% of control at 96 hr post-AlbuBChE dose.
Consistent with AlbuBChE mechanism of action, exposure to the cocaine metabolite ecgonine methyl ester increased ˜40 fold at 2 hr post-AlbuBChE administration and decreased as a function of time post-AlbuBChE dose.
AlbuBChE effect was less pronounced on the cocaine metabolite, benzoylecgonine.
PK/PD relationship in Squirrel monkeys appears to indicate an inverse relationship between AlbuBChE serum concentration and cocaine levels. AlbuBChE serum concentration that may result in 50% decrease in cocaine concentration (EC50) was estimated by the direct Inhibitory Effect Emax model to be ˜400 ng/mL. Due to the limited data and the assumptions used in the analysis, parameter values from this PK/PD analysis need to be viewed as approximate estimates.
Example 3 AlbuBChE A Cardiovascular Safety Pharmacology Study in Cynomolgus Monkeys with or without Administration of Cocaine ObjectiveTo evaluate the cardiovascular and respiratory safety of AlbuBChE administered by the intramuscular (IM) route in 3 male and 3 female cynomolgus monkeys. In addition, the effect of cocaine (administered by the intravenous (IV) route), AlbuBChE and their combination on cardiovascular safety was evaluated in another group of 3 male and 3 female cynomolgus monkeys.
Study DesignPrior to the start of the study, the monkeys were surgically instrumented with telemetry transmitters and vascular access ports. The following CV parameters were monitored: systolic pressure, diastolic pressure, mean arterial blood pressure, mean heart rate and mean rate-pressure product. Body temperatures changes were also monitored.
Study Group 1 (3 males and 3 females), served as a control group for testing the effect of AlbuBChE alone compared to its vehicle. Monkeys were administered (IM) with the control article AlbuBChE formulation buffer on Study Days (SDs) 1 and 4. Three hours post formulation buffer administration respiratory and cardiovascular (CV) parameters were recorded, respectively.
A single IM dose of the test article (AlbuBChE at 15 mg/kg) was administered on SD 8 and 11. Three hours after AlbuBChE dosing (corresponding to Tmax of AlbuBChE) CV and respiratory parameters were monitored, respectively.
The effect of pretreatment with AlbuBChE prior to cocaine dose on CV parameters was tested on the second group (Group 2) of animals (3 males and 3 females). First baseline CV parameters were recorded on SD 15 after an IM administration of AlbuBChE formulation buffer followed by a single IV administration of saline (cocaine vehicle), 3 hours later. The effect of cocaine on CV parameters was measured on SD 18, on which the animals received a single IM injection of AlbuBChE formulation buffer followed by a single IV dose of cocaine (1 mg/kg, IV), 3 hours later.
The effect of pretreatment with AlbuBChE on cocaine—induced changes in CV parameters was monitored on SD 22. CV parameters were recorded subsequent to a single IM dose of AlbuBChE (15 mg/kg) followed by a single IV dose of cocaine (1 mg/kg), 3 hours later (see Table 21).
All animals were observed at least twice a day for morbidity, mortality, injury, and availability of food and water. The physiological responses to test article administration, including blood pressure, heart rate, body temperature, and the electrocardiograph (ECG), were monitored.
All animals survived to study termination.
Study Group 1AlbuBChE at 15 mg/kg (IM)) did not produce any significant changes in the recorded CV parameters, nor in body temperature compared to baseline values determined with AlbuBChE formulation buffer, as shown in
Within two minutes post cocaine (1.0 mg/kg, IV) administration mean arterial blood pressure (MAP) was increased by about 35 mmHg above baseline value of 105 mmHg. Pre-treatment with 15 mg/kg AlbuBChE prior to cocaine dose showed that not only was the maximum blood pressure was decreased by AlbuBChE but the time to reversal of the effect was also truncated by 4.5 fold (17 minutes upon pretreatment with AlbuBChE prior to cocaine dose compared to 77 minutes when cocaine was given alone), as shown in
Administration of cocaine (1.0 mg/kg, IV) elicited a rapid increase in heart rate from a baseline value of 140 beats/min reaching a peak value of 240 beats/min (70% increase) within about 3 minutes. This cocaine—induced elevation in heart rate was sustained for about 15 min dissipating gradually and returning to baseline value 2 hours after cocaine administration. Pre-treatment with AlbuBChE blunted cocaine-induced rise in heart rate showing a rapid but moderate increase of 30% to a peak value of 182 beats/min within about 3 minutes. This mild increase in heart rate was reversed completely returning to baseline value already 30 minutes after cocaine dose, as shown in
Administration of cocaine (1.0 mg/kg, IV) resulted in a mild and step wise increase in body temperature with a peak value of 38.7° C. at 45 minutes post-dose compared to base line temperature of 38° C. Pre-treatment with AlbuBChE (15 mg/kg, IM) prior to cocaine dose caused only a subtle increase in body temperature to a value of 38.3° C., as shown in
Adult male squirrel monkeys (Saimiri sciureus) weighing 0.8 to 1.2 kg were used as subjects. All monkeys were individually housed in a humidity and temperature controlled room and had free access to water. The monkeys were fed following any experimental procedures an amount of food (Lab Diet 5045, PMI Nutrition International, Richmond, Ind.; Banana Softies, Bio-Serv, Frenchtown, N.J.) determined to maintain a stable weight. Fresh fruit, vegetables and environmental enrichment were also provided daily. The animal care facilities were fully accredited by AAALAC and all experiments were approved by the NIDA Intramural Research Program Animal Care and Use Committee.
Cocaine Self-AdministrationThree monkeys were trained to self-administer 30 μg/kg/inj i.v. cocaine. Details of the self-administration training procedure can be found elsewhere (Justinova et al., 2003). In brief, the monkeys were placed in a seated position in a Plexiglas restraint chair. The chair was enclosed in a larger acoustical chamber. On the front wall of the restraint chair there was a response lever and stimulus lights. A green light signaled the beginning of the session. The monkeys were trained to make 10 responses (fixed-ratio, FR, 10) to receive an i.v. injection of cocaine. The injection of cocaine was accompanied by the green light turning off and a yellow stimulus light being presented for 2 sec. Following each cocaine injection there was also a 60-sec timeout. At the end of the timeout, the green light was turned on. Sessions lasted for 1 hour. Occasionally, saline was substituted for cocaine. Following the establishment of stable cocaine self-administration and reliable extinction of responding following saline substitution, AlbuBChE (5 mg/kg, i.m.) or its vehicle (i.m.) were given 2 hours prior to a self-administration session. Self-administration responding was then measured for 5 consecutive days. Following each drug test or saline substitution, responding for 30 μg/kg/inj cocaine was reestablished for at least 5 days. Following reinstatement testing (see below), the dose of cocaine available for self-administration was lowered to 10 μg/kg/inj and the effect of AlbuBChE (5 mg/kg, i.m.) was again determined.
Reinstatement of Cocaine Self-AdministrationSaline was substituted for cocaine in monkeys that were reliably self-administering 30 μg/kg/inj i.v. cocaine. Responding rapidly decreased and remained at that low level over a number of days. The vehicle of AlbuBChE was then given 2 hrs before cocaine (0.3 mg/kg, i.v.), which was given 5 min prior to a session where saline was available for self-administration to determine whether cocaine would reinstate self-administration responding. The same dose of cocaine was also given prior to saline self-administration sessions 48 and 96 hours later. Subsequently, AlbuBChE (5 mg/kg, i.m.) was given 2 hours prior to a second sequence of 3 reinstatement tests with 0.3 mg/kg i.v. cocaine. Following these tests, the monkeys were returned to baseline where 30 μg/kg/inj cocaine was available for self-administration. Subsequently, saline was again substituted for cocaine and a second series of reinstatement tests were conducted in a similar manner except that 0.1 mg/kg i.v. cocaine was given prior to reinstatement sessions.
DrugsAlbuBChE was supplied by TEVA Pharmaceutical (Netanya, Israel) in a frozen solution at a concentration of 30 mg/ml. Once thawed the solution was diluted to 15 mg/ml with vehicle and then given to the monkeys in a volume of 0.33 ml/kg. Cocaine (NIDA, Baltimore, Md.) was prepared in sterile saline and given in a volume of 0.2 ml for self-administration. When given as a pretreatment for the reinstatement studies, cocaine was given in a volume of 0.3 ml/kg.
Data AnalysisThe blood level data were analyzed separately for each metabolite and time point (5 or 30 min). A one-way analysis-of-variance (ANOVA) was performed with follow-up Dunnett tests using the results of monkeys treated with vehicle as the control. The self-administration data were analyzed separately for response rate or injections following either vehicle treatment or AlbuBChE treatment. Control data were included in the analysis by taking the average of the last 3 days for the immediately preceding baseline condition. A within subjects ANOVA was then performed with follow-up tests contrasting days following vehicle or AlbuBChE with the control. For the reinstatement tests, a two-way ANOVA was performed for both response rate and injections, with time post vehicle or AlbuBChE as the within-subjects factor and pretreatment (vehicle or AlbuBChE) as the between subjects factor. Follow-up contrast compared vehicle and AlbuBChE at each time point.
ResultsIn monkeys self-administering 30 μg/kg/inj cocaine, AlbuBChE reduced self-administration. The panels of
Following reinstatement testing (see below), monkeys were returned to self-administration at a lower cocaine dose (10 μg/kg/inj). Decreasing the maintenance dose decreased rate of responding and number of injections (
Neither response rate nor injections significantly changed following vehicle injection compared to the average of the last 3 days on baseline. AlbuBChE (5 mg/kg) was then given and cocaine self-administration continued for an additional 5 days. Both response rate and injections were decreased 2 hrs following the AlbuBChE injection, but these effects failed to reach significance.
In monkeys that were responding for 30 μg/kg/inj cocaine, substituting saline for cocaine lead to a rapid decrease in responding. The AlbuBChE vehicle was then given i.m. Two, 48 and 96 hrs later 0.3 mg/kg cocaine i.v. was given 5 min before a saline substitution session. The administration of cocaine led to a reinstatement of cocaine self-administration responding as shown in the black bars in the left panels of
In 4 monkeys that were trained to discriminate 0.6 mg/kg methamphetamine from saline, cocaine fully substituted for methamphetamine at a dose of 0.3 mg/kg (
The monkeys trained to self-administer cocaine and also tested on the reinstatement procedure received a total of 4 injections of AlbuBChE. Blood was taken for determination of AlbuBChE antibodies after the first, second and fourth AlbuBChE injections. Following the first 2 injections, antibody levels were below the level of detection (titer level of 20). Following the fourth injection, however, antibody levels appeared elevated. In 2 monkeys the antibody titer was slightly elevated over the limit of detection (21 and 43). For the third monkey, antibody levels were clearly elevated (643). The concentration of AlbuBChE in the blood for this monkey one week following the AlbuBChE injection was also reduced (27 ng/ml vs 55 and 53 ng/ml for the other 2 monkeys).
DiscussionThe results of these studies clearly show that pretreatment with a modified form of BChE is effective in antagonizing the behavioral effects of cocaine in a non-human primate. This work extends previous work with this compound in rodents, where it was shown that AlbuBChE could antagonize the toxic effects of cocaine in rats and also block cocaine-induced reinstatement of cocaine self-administration (Brimijoin et al., 2008). Here, pretreatment with 5 mg/kg AlbuBChE reduced both response rate and injections in monkeys self-administering 30 μg/kg/inj cocaine. In these same monkeys tested for reinstatement of cocaine self-administration following self-administration extinction, 5 mg/kg AlbuBChE was capable of blocking reinstatement of responding by either 0.3 mg/kg or 0.1 mg/kg cocaine. When the dose available for self-administration was reduced to 10 μg/kg/inj, AlbuBChE again appeared to reduce the response rate and number of injections received, although these effects with 10 μg/kg/inj cocaine were more variable and failed to reach significance. Finally, the 5 mg/kg dose of AlbuBChE was also able to antagonize the generalization of cocaine to a methamphetamine discriminative stimulus, but this effect was specific to cocaine as AlbuBChE was not able to antagonize the discriminative stimulus effects of methamphetamine.
When tested against 30 μg/kg/inj cocaine self-administration, the effects of AlbuBChE were still evident 3 days later, although at a reduced effectiveness. On reinstatement and discrimination, however, the effects of AlbuBChE were not evident 48 hours following treatment. The half-life of AlbuBChE was shown to be around 56 hours and effects on cocaine metabolism were still evident 72 hours after AlbuBChE administration, so it might have been expected that some effect on these procedures would have been evident at 72 hours. A number of factors could contribute to this failure to see a reduction in reinstatement or cocaine generalization at 72 hrs. During self-administration smaller doses of cocaine are given over an extended period of time. In the other procedures a relatively larger dose of cocaine was administered as a bolus injection. It may be easier for AlbuBChE to metabolize the cocaine before it reaches the brain under the self-administration conditions than under the other conditions. When AlbuBChE metabolizes cocaine under self-administration, its effect is to institute extinction conditions. Behavioral recovery from extinction may also prolong the effects of AlbuBChE treatment on self-administration. In the reinstatement study, responding produced saline and the stimulus previous associated with reinforcement. When the monkeys reinstated responding following a cocaine injection, the monkeys still received saline for responding, but they also received the stimulus previously associated with cocaine. The presentation of this stimulus may also have facilitated continued responding under the reinstatement conditions (Spealman et al., 1999), masking some of the effect of AlbuBChE.
The effects of AlbuBChE were almost certainly related to its effects on the metabolism of cocaine. The administration of AlbuBChE decreased the amount of cocaine in the blood for at least 72 hours. The fact that EME levels were also increased for at least 72 hours following AlbuBChE suggests that AlbuBChE was metabolizing cocaine similarly to native BChE (Jones, 1984). This time course for cocaine metabolism is similar to that seen for the self-administration experiment where the monkeys were reinforced with 30 μg/kg/inj cocaine. Further, AlbuBChE had no effect on response rate in the discrimination study, suggested that it does not produce a non-specific effect on operant responding independent of the presence of cocaine in the blood.
The observation of relatively high levels of AlbuBChE antibodies in one monkey following its fourth injection indicates that AlbuBChE might lose some of its effectiveness over multiple injections. While the results for that one particular monkey did not appear to be different from the other 2 monkeys tested, the observation of antibodies suggests that some of the AlbuBChE would be bound by antibodies which might decrease its ability to metabolize cocaine. Further work will be needed to determine how prevalent the antibody production is in primates and whether the levels of antibody observed are sufficient to decrease the effectiveness of AlbuBChE in metabolizing cocaine.
Cocaine continues to show up in both emergency room mentions and medical examiner reports in the DAWN surveys. As such, a drug that could counteract the toxic effects of cocaine may be useful adjunct to emergency room treatment for patients abusing cocaine. An advantage of using a drug that metabolizes cocaine is that it will be specific for cocaine and should have minimal side effects. However, it would be necessary to confirm that a patient is using cocaine as AlbuBChE would not be effective against toxicity produced by other drugs of abuse, such as the amphetamines, that might produce a similar spectrum of toxic effects.
In addition to treating the toxic effects of cocaine, AlbuBChE might also be useful as an adjunct to other treatments for cocaine abuse. A person with a sufficient blood level of AlbuBChE who takes cocaine would be expected to experience a reduced subjective effect of cocaine. In the context of the current study, this translates to less cocaine self-administration, reduced reinstatement of cocaine self-administration and the failure of cocaine to generalize to the methamphetamine discriminative stimulus. As relapse to cocaine abuse remains a problem in treatment, the reduced subjective effects of cocaine would be expected to reduce relapse. For someone undergoing treatment that does relapse to use, the presence of AlbuBChE in the blood would metabolize much of the cocaine and potentially reduce the likelihood of continued cocaine use. This would require an individual to continue taking AlbuBChE throughout the period of time that relapse would be expected. Therefore, it will be critical to determine how prevalent the development of antibodies to AlbuBChE is and how that might effect its ability to metabolize cocaine.
In conclusion, pretreatment of squirrel monkeys with AlbuBChE was able to reduce the amount of cocaine in the blood following a cocaine bolus treatment. Pretreatment with AlbuBChE was also able to reduce cocaine self-administration in monkeys that had been trained to self-administer 10 and 30 μg/kg/inj cocaine. AlbuBChE was able to block cocaine-induced reinstatement of cocaine self-administration for 2 different doses of cocaine. Finally, AlbuBChE was also able to antagonize the discriminative effects of cocaine in squirrel monkeys. The finding that AlbuBChE was able to antagonize the behavioral effects of cocaine in 3 different models of cocaine's behavioral effects suggests that it should be effective as a potential treatment of cocaine abuse.
Example 5 A Double-Blind, Placebo-Controled, Single Ascending Dose of AlbuBChE Followed by Multiple Doses of Cocaine to Evaluate the Pharmacokinetic and Pharmacodynamic Parameters of Cocaine after AlbuBChE Administration in Cocaine Recreational Volunteers ObjectiveTo determine cocaine blood levels following multiple doses subsequent to AlbuBChE administration, and to determine the behavioral, psychological and safety effects of cocaine following multiple doses subsequent to AlbuBChE administration. To evaluate the pharmacokinetics, safety, and tolerability of AlbuBChE.
Study DesignThis is a 5-arm, parallel-group, active and placebo-controlled, double blind, randomized study, to compare treatment with AlbuBChE with placebo as a negative control.
Forty (40) non-treatment seeking healthy adults who have used cocaine are randomly assigned to five (5) treatment groups. Each group will contain eight subjects.
Group A (low dose): Subjects receive a single, intramuscular injection of 50 mg of AlbuBChE.
Group B (intermediate dose): Subjects receive a single, intramuscular injection of 100 mg of AlbuBChE.
Group C (high-intermediate dose): Subjects receive a single, intramuscular injection of 150 mg of AlbuBChE.
Group D (high dose): Subjects receive a single, intramuscular injection of 300 mg of AlbuBChE.
Group E (negative control): Subjects receive a single, intramuscular injection of placebo.
The study is divided to 5 cohorts of 8 subjects per cohort with 2 to 3 days apart.
Inpatient Hospital PhaseSubjects remain resident in the clinic from the evening before Day 1 (check in; Day −1) until the morning of Day 11. Subjects return to the clinic for follow-up visit on Day 18±2.
Day −1: On the morning of day −1, a 40 mg intravenous dose of cocaine is administered.
Day 1: A single, intramuscular dose of AlbuBChE or placebo is administered.
Day 1, 4, 8 and 10: On Day 1, at AlbuBChE Cmax (3 hours post dose) and at the morning of days 4 (72 hours), 8 (168 hours) and 10 (216 hours) at the corresponding time of AlbuBChE/placebo administration, a 40 mg intravenous challenge dose of cocaine is administered.
Saline infusions are included (randomized with cocaine infusions, administered 2 hours apart) on each day of cocaine administration, and have the infusion type order single blinded.
Study Drug AdministrationPlanned AlbuBChE doses are as described above for groups A-E. Each subject receives a single dose of AlbuBChE or placebo by intramuscular (IM) injection. 40 mg of cocaine hydrochloride, prepared as a 1 mg/ml saline solution is injected into a forearm vein at the rate of 1 mg/second using a constant rate infusion pump.
Study DurationThe duration of the study (from screening until the End of Study (EOS) visit) for each subject is approximately 11 to 12 weeks.
Study PopulationA total of Forty (40) male subjects aged 18-55 who are recreational cocaine users. Subjects who discontinue the study for any reason after dosing are not replaced.
Main Inclusion/Exclusion Criteria Inclusion Criteria
- 1. Male volunteers aged 18-55 years, inclusive;
- 2. Body mass index (BMI) 18-33 kg/m2 and weight of at least 50 kg;
- 3. Healthy, as determined by no clinically significant medical history, physical examination, electrocardiogram (ECG), vital signs and laboratory results at screening;
- 4. Currently use cocaine by smoking, intranasal or i.v. route; defined as at least once in a month prior to screening, 6 times in the past year and 20 times over lifetime. Current use is confirmed through a positive Urine Drug Test (UDS) prior to in-patient period (i.e. at screening or between screening and Day −1);
- 5. Able to understand the nature of the trial and any hazards of participating in it;
- 6. Able to communicate satisfactorily with the Investigator and to participate in, and comply with the requirements of the entire trial; and
- 7. Willingness to give written consent to participate, after reading the information and consent form and after having the opportunity to discuss the trial with the Investigator or his delegate and sign the Informed Consent.
- 1. Current or history of alcohol or drug dependence according to DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders—last version) criteria (excluding nicotine and caffeine), or participation in rehabilitation program (except smoking cessation);
- 2. History of severe allergic or anaphylactic reactions;
- 3. Known allergy or hypersensitivity to natural or recombinant butyryl cholinesterase (BChE), human serum albumin (HSA) or any other component of the formulation;
- 4. History of any clinically significant (as determined by the Principal Investigator) cardiac, endocrine, haematological, hepatic, immunological, metabolic, urological, pulmonary, neurological, dermatological, psychiatric, renal, or other major disease;
- 5. History of any malignant disease;
- 6. Major trauma or surgery in the 2 months before screening or at any time between screening and check-in;
- 7. Acute infection within 2 weeks before screening or at any time between screening and check-in;
- 8. Clinically significant abnormal ECG findings at screening or check-in visits, as determined by the Principal Investigator;
- 9. Blood pressure outside the ranges 90-140 mmHg systolic or 45-90 mmHg diastolic (measured after a rest of at least 5 min) at screening or check-in. Blood pressure may be re-tested in the supine position at intervals of 5-10 min. The pressure elevation is considered sustained if either the systolic or the diastolic pressure exceeds the stated limits after three assessments, and thus the subject may not be randomized;
- 10. Heart rate <40 beats/min (measured after a rest of at least 5 min) at screening or check-in;
- 11. Known history of or a positive test result for human immunodeficiency virus (HIV) types 1 or 2 at screening;
- 12. Known history of, or a positive test result for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) at screening;
- 13. Use of prescription or over-the-counter (OTC) medication (other than paracetamol (acetaminophen), ≦2 g/day or ibuprofen, 650 mg/day), investigational drugs, vitamins, or herbal remedies, within 2 weeks before dosing or within 5 half-lives before dosing, whichever is longer;
- 14. Participation in another clinical trial of a new chemical entity or a prescription medicine within the 3 months before dosing or within 5 half-lives before dosing, whichever is longer;
- 15. Loss of >400 mL blood (e.g. as a blood donor) within 2 months before dosing, or received any blood, plasma, or platelet transfusions within 3 months before check-in, or who have planned donations during the study or within 3 months after the study;
- 16. Subject consumes greater than 20 cigarettes per day on average, in the month prior to screening, or be unable to abstain from smoking (or use of any nicotine-containing substance) for at least 6 hours (so that all pre-dose and post-dose/infusion-related assessments can be completed uninterrupted);
- 17. Positive UDS for amphetamine, cocaine (only on at Day −1), opioids, cannabinoids, and benzodiazepines. Positive result for benzodiazepines and cannabinoids acceptable as long as stable or decreasing due to long half-lives. Positive UDS for other drugs will result in rescheduling at discretion of investigator/designee; Positive breath alcohol test will also result in rescheduling at discretion of investigator/designee;
- 18. Exposure to pesticides or any other organophosphates (e.g. agricultural workers);
- 19. Inability to participate or successfully complete the study, in the opinion of their general practitioner or the Investigator, because the volunteer is:
- a. mentally or legally incapacitated, or unable to give consent for any reason;
- b. in custody due to an administrative or a legal decision, or under supervised parole, or being admitted to a sanitarium or social institution;
- c. unable to be contacted in case of emergency; or
- d. unlikely to cooperate or comply with the clinical study protocol or is unsuitable for any other reason.
Vital signs, including blood pressure, heart rate (part of the PD parameters) and body temperature are monitored. Physical examinations, clinical laboratory tests, and 12-lead ECGs are performed, with 12-lead ECGs after each cocaine infusion, at pre-infusion, 30 minutes and 2 hours post-infusion, and 8 hour post-first infusion. Telemetry is performed for 4 hours immediately after each cocaine injection.
Samples for BChE and acetyl cholinesterase (AChE) activity are collected but are not all necessarily assayed. The activity of BChE and AChE is determined using a colorimetric method based on the Ellman assay, which serves as a neutralization assay for the endogenous enzymes. Sampling timepoints are at screening, pre-dose and 168 hours (Day 8), 240 hours (Day 11) and follow-up (Day 18±2) post-dose. The blood tests for Ellman assay take place before administration of cocaine (where relevant).
Intravenous infusions of cocaine are immediately terminated if any of the following occur:
1. Systolic BP of 180 mm Hg or greater;
2. Diastolic BP of 100 mm Hg or greater;
3. HR of 130 bpm or greater; or
4. Behavioral manifestations of psychostimulant toxicity (agitation, psychosis, or inability to cooperate with study procedures).
Subjects are considered to have not tolerated IV cocaine infusions if any of the following occur:
1. Acute chest pain or shortness of breath;
2. Systolic BP of 180 mm Hg or greater;
3. Diastolic BP of 120 mm Hg or greater;
4. HR of [220−age X 0.85] bpm or greater (i.e., >than 170 bpm for a 20 year old subject);
5. Neurologic or psychiatric events (e.g., panic or psychosis);
6. Clinically significant ECG abnormalities (including heart block, three or more sustained ectopic ventricular beats, or tachyarrhythmias);
7. Stopping criteria for further cocaine infusion do not return to acceptable limits within appropriate time frames (e.g., 30 min);
8. Stopping criteria for further cocaine infusion are met for a second time within the protocol; or
9. Any condition that in the clinical judgment of the PI that is of sufficient magnitude to present a danger to the subject.
Local tolerability and pain (evaluated by the visual analogue scale (VAS)) at the injection site are evaluated during the first 24 h after dosing. Timepoints are: 20 min, 1, 2, 4, 8 and 24 hours post AlbuBChE dose.
Adverse events (AEs) are monitored throughout the study.
Immunogenicity (IG)Samples for immunogenic levels are collected but are not all necessarily assayed. Titers for antibodies against HSA, human butyryl cholinesterase (hBChE) and AlbuBChE are evaluated. Sampling timepoints are: pre-dose and 168 hours (Day 8), 240 hours (Day 11) and follow-up (Day 18±2) post-dose. The blood tests for IG assays take place before administration of cocaine (where relevant).
Pharmacokinetic Variables and SamplingTo determine serum concentration of AlbuBChE, blood samples are collected before dosing and at several time points after dosing. Where the data permits, the following pharmacokinetic (PK) parameters are calculated:
- Cmax maximum observed serum concentration
- tmax time to achieve Cmax
- AUC(0-t) area under the serum concentration-time curve from 0 h to the time of the last quantifiable concentration
- AUC(0-∞) area under the serum concentration-time curve extrapolated to infinity
- AUCext percentage of AUC(0-∞) due to extrapolation from tlast to infinity
- Vd/f apparent volume of distribution during terminal phase
- CL/f apparent total body clearance
- λz terminal elimination rate constant, estimated by linear regression on the terminal phase of the semi-logarithmic concentration versus time curve
- t1/2 apparent terminal elimination half-life
- MRT mean residence time
Additional parameters may be calculated if deemed necessary. Sampling timepoints for PK of AlbuBChE in serum are as follows: pre-dose and 20, 40 min, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours, 18 hours, 24 hours (Day 2), 36 hours (Day 2), 48 hours (Day 3), 72 hours (Day 4), 96 hours (Day 5), 120 hours (Day 6), 144 hours (Day 7), 168 hours (Day 8), 192 hours (Day 9), and 216 hours (Day 10) post-dose. Where applicable, sampling timepoints for PK of AlbuBChE are taken just before cocaine infusion.
Pharmacodynamics Variables and SamplingBlood samples are collected before dosing and at several time-points after each dosing of cocaine. In vivo cocaine levels (and its metabolites benzoylecgonine and ecgonine methyl ester) are determined by validated LC/MS-MS method and are correlated to AlbuBChE blood levels. Cocaine exposure (Cmax, tmax, AUC(0-t), AUC(0-∞) and Vd) and clearance (CL, λz, t1/2) are determined. PD sampling timepoints of cocaine levels in serum after each cocaine dose are as follows: pre-dose, 2, 5, 10, 15, 30, 45, 60, 90, and 120 minutes post dose.
Blood pressure and heart rate are measured pre-infusion and 2, 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, and 300 minutes post infusion.
Behavioral and Psychological Effects (Subjective Effects)Subjective effects are measured using a computerized (21 CFR 11 validated) visual analogue scale (VAS). The time points for collection of subjective effects match with those for cocaine blood samples. The following set of VAS are: Drug Liking, Take Drug Again, Overall Drug Liking, High, Good Effects, Bad Effects, Feeling Rush, Desire for Cocaine, Feeling Anxious, Over-Stimulated, and Any Drug Effects.
PD sampling timepoints of VAS parameters after each cocaine dose are as follows: pre-dose, 2, 5, 10, 15, 30, 45, 60, 90, and 120 minutes post dose.
Urine CollectionUrine is collected for metabolic investigations over a 52 hour interval after cocaine administration on Day −1, Day 4 and Day 8. The collection ranges are: (i) immediately after cocaine dose, followed by collection intervals of (ii) two intervals of three hours, and (iii) nine intervals of six hours.
Statistical Analysis PharmacokineticsPK parameters are derived from serum concentrations for each dose level (number of subjects, mean, SD, geometric mean (for AUCs and Cmax), coefficient of variation, minimum, median, and maximum). Dose proportionality (for AlbuBChE only) using the power model is evaluated for Cmax, AUC0-t, and AUC0-∞.
PharmacodynamicsTime course of PD effects (subjective and objective) is determined. PD parameters include: Emax (maximum effect), TEmax (time to Emax), time averaged area under the effect curve (TA_AUE), partial AUE for early time points, and cumulative AUE.
SafetySafety data is determined using descriptive statistics and change from Baseline, where appropriate, for each treatment group. AEs are coded using the latest version of the Medical Dictionary for Regulatory Activities (MedDRA) and summarized by system organ class and preferred term.
BioanalyticalFrozen serum samples for determining AlbuBChE concentrations and antibodies are shipped on dry ice for analysis. Analyses of cocaine and metabolite levels is performed using validated methods.
Results Safety, Tolerability and ImmunogenicityAlbuBChE is safe to administer to humans. No significant safety issues are observed with intramuscular (IM) AlbuBChE doses of mg to 300 mg. AlbuBChE is well tolerated, with no unacceptable side effects. Local tolerability and pain at the IM injection site are acceptable, with no significant adverse events. The administration of 50 mg to 300 mg of AlbuBChE as a single dose does not provoke a significant immune response. Titers for antibodies agains HSA, human butyryl cholinesterase (hBChE) and AlbuBChE are all within acceptable limits.
Pharmacokinetic VariablesMaximum observed serum concentration of AlbuBChE, Cmax, increases with increasing dose of AlbuBChE. AlbuBChE absorption from the IM site of administration is rapid, with a short time to achieve Cmax. AUC(0-t) and AUC(0-∞) indicate that AlbuBChE levels persist for a significant and clinically useful amount of time. Vd/f values indicate that the majority of AlbuBChE is present in the circulation during the terminal phase. CL/f values indicate that AlbuBChE is cleared from the body at an acceptable rate. Apparent terminal elimination half-life values indicate a weekly or twice weekly dosing of AlbuBChE to maintain therapeutic levels. The mean residence time of AlbuBChE is within clinically acceptable limits.
Pharmacodynamic VariablesMaximum observed serum concentration of cocaine, Cmax, decreases with increasing dose of AlbuBChE. Cmax levels are achieved very rapidly following a 40 mg intravenous dose of cocaine, with a short tmax. AUC(0-t) and AUC(0-∞) of cocaine and its metabolites benzolyecgonine and ecgonine methyl ester indicate that cocaine is more rapidly metabolized in subjects receiving a dose of AlbuBChE prior to cocaine exposure than subjects receiving placebo. Cocaine AUC(0-t) decreases as a function of AlbuBChE dose and increases as a function of time post-AlbuBChE administration. Vd values indicate that the majority of cocaine is present in the circulation during the terminal phase. CL values indicate more rapid cocaine clearance following administration of AlbuBChE compared to placebo, with clearance rate decreasing as time post AlbuBChE administration increases. Similarly, apparent terminal elimination half-life values indicate more rapid cocaine clearance following administration of AlbuBChE compared to placebo, with clearance rate decreasing as time post AlbuBChE administration increases.
Behavioral and Phychological EffectsSubjects administered AlbuBChE report significantly different results on the visual analogue scale (VAS) compared to subjects administered placebo. AlbuBChE administration decreases cocaine liking. AlbuBChE administration decreases the desire to take cocaine again. AlbuBChE administration decreases overall drug liking. AlbuBChE administration decreases the “high” associated with cocaine exposure. AlbuBChE administration decreases the subjective feeling of “good effects” after cocaine exposure. AlbuBChE administration decreases subjective feeling of “rush” associated with cocaine exposure. AlbuBChE administration decreases the desire for cocaine. AlbuBChE administration reduces feelings of anxiousness following cocaine exposure. AlbuBChE administration reduces feelings of being over-stimulated following cocaine exposure. AlbuBChE administration reduces the reporting of “any drug effects.”
Subjects administered AlbuBChE prior to cocaine exposure do not report significantly different “bad effects” following AlbuBChE administration compared to subjects administered placebo. AlbuBChE reduces the feeling of “bad effects” following cocaine exposure.
DiscussionThe present Example determines cocaine blood levels following multiple doses of cocaine subsequent to AlbuBChE administration, and determines the behavioral, psychological and safety effects of cocaine following multiple doses subsequent to AlbuBChE administration in an inpatient setting.
The primary measure of a successful treatment of cocaine abuse and dependence in an outpatient setting is a period of abstinence during and following treatment. The facilitation of a period of abstinence, such as a two or three week period of abstinence, indicates a successful treatment. Secondary outcome measures include reduction in cocaine levels or amount of cocaine intake, overall proportion of cocaine non-use days, proportion of successful subjects, the largest number of consecutive cocaine non-use days, and severity of cocaine dependence as evaluated, for example, by the cocaine selective severity assessment (CCSA).
Previous studies have found that AlbuBChE has a half life of approximately 8 hours in rats and have speculated that the potential half-life of AlbuBChE would range from 1 to several days in humans. (Brimijoin et al., 2008; Gao et al. 2009). Gao et al. noted that the observed half-life of monomeric AlbuBChE in rats is shorter than that of native tetrameric BChE, and speculated that the half-life of AlbuBChE could be increased by post-translational modifications such as polyethylene glycosylation.
The present Example determines that the half-life of AlbuBChE when administered by intramuscular injection is dose dependent, with half-life values increasing with increasing dose. The half-life values at the specified dosages allow for a weekly or twice weekly dosing schedule without the need for post-translational modifications such as polyethylene glycosylation.
Previous studies have also reported that intravenous administration of AlbuBChE to rats can cause a modest increase in blood pressure and mild lethargy. (Brimijoin et al. 2008). In constrast, a significant increase in blood pressure is not observed when AlbuBChE is administered to humans by intramuscular injection, nor is lethargy reported in a significant number of subjects.
Human subjects administered AlbuBChE do not report a significant increase in cocaine cravings. In contrast, desire to use cocaine is significantly decreased following AlbuBChE dosing and remains significantly depressed for up to one week following a single administration of AlbuBChE.
The findings of the present Example indicate that intramuscular administration of AlbuBChE to humans at the specified dosages does not result in any unacceptable side effects and that the specified dosages will allow for the successful treatment of biological effects of cocaine exposure.
REFERENCES
- Brimijoin, S., Gao, Y., Anker, J. J., Gliddon, L. A., LaFleur, D., Shah, R., Zhao, Q., Singh, M., and Carroll, M. E., “A Cocaine Hydrolase Engineered from Human Butyrylcholinesterase Selectively Blocks Cocaine Toxicity and Reinstatement of Drug Seeking in Rats”. Neuropsychopharmacology, 33: 2715-2725, 2008.
- Brogan, W. C. 3rd, Kemp, P. M., Bost, R. O., Glamann, D. B., Lange, R. A., Hillis, L. D., “Collection and handling of clinical blood samples to assure the accurate measurement of cocaine concentration,” J. Anal. Toxicol. 1992 May-June; 16(3):152-4.
- Davies, B. and Morris, T., “Physiological parameters in laboratory animals and humans,” Pharm. Res., 10: 1093-1095, 1993.
- Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Publishing, Inc.; 4th edition (June 2000)
- “Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers,” U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER), July 2005.
- Pan, Y., Gao, D., Yang, W., Cho, H., Yahg, G., Tai, H., Zhan, C., “Computational redesign of human butyrylcholinesterase for anticocaine medication,” PNAS, 102(46):16656-61, 2005.
- Sun, H., Shen, M., Pang, Y., Lockridge, O., Brimijoin, S., “Cocaine Metabolism Accelerated by a Re-Engineered Human Butyrylcholinesterase,” Journal of Pharmacology and Experimental Therapeutics, 302(2): 710-16, 2002.
- US Patent Application Publication No. 2008/0194481, published Aug. 14, 2008 (U.S. Ser. No. 11/932,823, filed Oct. 31, 2007).
- Gao, et al. (2009) “An Albumin-Bytyrylcholinesterase for Cocaine Toxicity and Addiction: Catalytic and Pharmacokinetic Properties,” NIH Public Access Author Manuscript, published in final edited form as Chem. Biol. Interact. 2008 Sep. 25; 175(1-3): 83-87.
Claims
1. A method of attenuating a biological effect of a cocaine exposure in a primate comprising administering to the primate an amount of a fusion protein comprising: (SEQ ID NO: 1) EDDIIIATKNGKVRGMNLTVFGGTVTAFLGIPYAQPPLGRLRFKKPQSLT KWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDCLYLNVWIP APKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGA LGFLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESSG AASVSLHLLSPGSHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLT GCSRENETEIIKCLRNKDPQEILLNEAFVVPYGTPLGVNFGPTVDGDFLT DMPDILLELGQFKKTQILVGVNKDEGTWFLVGGAPGFSKDNNSIITRKEF QEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDVVGDYNFIC PALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPL ERRDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKY LTLNTESTRIMTKLRAQQCRFWTSFFPKV, (SEQ ID NO: 2) DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFA KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDD FAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL, and wherein the amount of the fusion protein is effective to cause attenuation of the biological effect of the cocaine exposure in the primate.
- (a) a mutant butyrylcholinesterase (BChE) polypeptide comprising the sequence
- (b) a human serum albumin (HSA) polypeptide comprising the sequence
- (c) a signal peptide comprising the sequence MRPTWAWWLFLVLLLALWAPARG (SEQ ID NO:3),
2. The method of claim 1, wherein the fusion protein comprises the sequence (SEQ ID NO: 4) MRPTWAWWLFLVLLLALWAPARGEDDIIIATKNGKVRGMNLTVFGGTVTA FLGIPYAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFH GSEMWNPNTDLSEDCLYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHV YDGKFLARVERVIVVSMNYRVGALGFLALPGNPEAPGNMGLFDQQLALQW VQKNIAAFGGNPKSVTLFGESSGAASVSLHLLSPGSHSLFTRAILQSGSF NAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEILLNEA FVVPYGTPLGVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGT WFLVGGAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWV DDQRPENYREALGDVVGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSK LPWPEWMGVMHGYEIEFVFGLPLERRDNYTKAEEILSRSIVKRWANFAKY GNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMTKLRAQQCRFWTSFFP KVDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTE FAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPER NECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPY FYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRL KCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHG DLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEM PADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLR LAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQL GEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPC AEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYV PKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVM DDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL.
3-45. (canceled)
46. A method of attenuating a biological effect of a cocaine exposure in a primate comprising administering to the primate an amount of a fusion protein comprising: (SEQ ID NO: 1) EDDIIIATKNGKVRGMNLTVFGGTVTAFLGIPYAQPPLGRLRFKKPQSLT KWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDCLYLNVWIP APKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGA LGFLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESSG AASVSLHLLSPGSHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLT GCSRENETEIIKCLRNKDPQEILLNEAFVVPYGTPLGVNFGPTVDGDFLT DMPDILLELGQFKKTQILVGVNKDEGTWFLVGGAPGFSKDNNSIITRKEF QEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDVVGDYNFIC PALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPL ERRDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKY LTLNTESTRIMTKLRAQQCRFWTSFFPKV, and (SEQ ID NO: 2) DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFA KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDD FAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL, wherein the amount of the fusion protein is effective to cause attenuation of the biological effect of the cocaine exposure in the primate.
- (a) a mutant butyrylcholinesterase (BChE) polypeptide comprising the sequence
- (b) a human serum albumin (HSA) polypeptide comprising the sequence
47. The method of claim 46, wherein the fusion protein comprises the sequence (Residues 24 to 1137 of SEQ ID NO: 4) EDDIIIATKNGKVRGMNLTVFGGTVTAFLGIPYAQPPLGRLRFKKPQSLT KWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDCLYLNVWIP APKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGA LGFLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESSG AASVSLHLLSPGSHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLT GCSRENETEIIKCLRNKDPQEILLNEAFVVPYGTPLGVNFGPTVDGDFLT DMPDILLELGQFKKTQILVGVNKDEGTWFLVGGAPGFSKDNNSIITRKEF QEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDVVGDYNFIC PALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPL ERRDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKY LTLNTESTRIMTKLRAQQCRFWTSFFPKVDAHKSEVAHRFKDLGEENFKA LVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFG DKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVD VMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQA ADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQ RFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSI SSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESEDVCKNYAE AKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYA KVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTP TLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSD RVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKER QIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEE GKKLVAASQAALGL.
48. The method of claim 46, wherein the fusion protein is administered by intramuscular injection.
49. A pharmaceutical composition comprising: (SEQ ID NO: 1) EDDIIIATKNGKVRGMNLTVFGGTVTAFLGIPYAQPPLGRLRFKKPQSLT KWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDCLYLNVWIP APKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGA LGFLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESSG AASVSLHLLSPGSHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLT GCSRENETEIIKCLRNKDPQEILLNEAFVVPYGTPLGVNFGPTVDGDFLT DMPDILLELGQFKKTQILVGVNKDEGTWFLVGGAPGFSKDNNSIITRKEF QEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDVVGDYNFIC PALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPL ERRDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKY LTLNTESTRIMTKLRAQQCRFWTSFFPKV, and (SEQ ID NO: 2) DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFA KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDD FAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL, and
- (I) a fusion protein comprising:
- (a) a mutant butyrylcholinesterase (BChE) polypeptide comprising the sequence
- (b) a human serum albumin (HSA) polypeptide comprising the sequence
- (II) a formulation buffer comprising 10 mM sodium phosphate, 200 mM mannitol, 60 mM trehalose, and 0.01% (w/v) polysorbate 80, pH 7.2.
Type: Application
Filed: Sep 4, 2013
Publication Date: Mar 6, 2014
Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD. (Petach-Tikva)
Inventors: Liora Sklair-Tavron (Zichron Yaakov), Moti Rosenstock (Menashe), Liron Shemesh-Darvish (Ramat-Gan), Hussein Hallak (Jerusalem), Victor Piryatinsky (Netanya), Viktor Roschke (Bethesda, MD), David Lafleur (Washington, DC)
Application Number: 14/018,271
International Classification: C07K 14/00 (20060101); C07K 14/765 (20060101); C12N 9/18 (20060101);
